Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from BFORE

The multinational phase 3 BFORE study compared bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Five-year follow-up results have now been published. Cumulative MMR, MR⁴, and MR^4.5 were higher with bosutinib than with imatinib. Overall, there were no new safety signals. The authors conclude that these results support 400-mg once-daily bosutinib as standard-of-care for newly diagnosed CP CML.